| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[17] NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Affordable Medicines, EDP-Adult Hospital level. NSAIDs – comparative review of efficacy and safety, 15 January2018. http://www.health.gov.za
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Research & Therapy 2015;17:66. https://www.ncbi.nlm.nih.gov/pubmed/25879879
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016;375:2519-29. https://www.ncbi.nlm.nih.gov/pubmed/28379793
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769–79. https://www.ncbi.nlm.nih.gov/pubmed/23726390
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086. https://www.ncbi.nlm.nih.gov/pubmed/21224324
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Ong CKS, Lirk P, Tan Ch, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clinical Medicine and Research 2007; 5(1):19-34. https://www.ncbi.nlm.nih.gov/pubmed/17456832
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Stam WB, Jansen JP, Taylor SD. Efficacy of etoricoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. The Open Rheumatology Journal 2012; 6:6-20. https://www.ncbi.nlm.nih.gov/pubmed/22582102
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Saf. 2014 Nov;37(11):897-902. https://www.ncbi.nlm.nih.gov/pubmed/25079141
NSAIDs as a therapeutic class (diclofenac, naproxen, ibuprofen): South African Medicines Formulary. 12th Edition. Division of Clinical Pharmacology. University of Cape Town, 2016.